John Glencross was asked by BBC Newsnight to comment on the position for investors during the ongoing Brexit negotiations. To watch the short clip please see below. [youtube id=”StTC1jD2Emc” align=”center” mode=”normal” autoplay=”no”]
Archives for August 2018
Calculus Capital portfolio company CEO, Leo de Montaignac of Weedingtech writes for The Parliament Magazine around the use of glyphosate in public and urban spaces. The primary objective for their product Foamstream was to offer an effective, affordable commercial product … Continued
As part of our ‘Spotlight On’ series, we focus on Blu Wireless Technology a technology company, developing semiconductor designs for the next generation of high speed wireless data transfer. Calculus Capital completed a £2.4m investment in Blu Wireless (‘BWT’) in June 2017, … Continued
As part of our ‘Spotlight On’ series, we focus on AnTech a specialist engineering company in the oil and gas industry. AnTech Limited has two different businesses: manufacturing products for use mainly in oil and gas production (as opposed to drilling) and … Continued
C4X recently announced that their C4X3256 programme has been awarded a grant from the National Institute on Drug Abuse (NIDA, a division of National Institute of Health (NIH)). The grant of approximately $480k will support the pre-clinical development of C4X3256 in cocaine … Continued
News of Benito’s Hat growth investment makes the headlines in this morning’s publication of City AM! Read more via the link below. Benito's Hat eyes expansion after securing new funding https://t.co/v7h7swSNAg pic.twitter.com/mbLFrPs6Vo — City A.M. (@CityAM) August 6, 2018
Calculus Capital portfolio company Mologic announced today that they have commenced a clinical trial to evaluate the company’s urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients. The study aims to identify five urinary biomarkers associated with … Continued
London, 3 August 2018: Calculus Capital has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments. OBT has a strong pipeline of ‘immune-oncology’ (IO) therapies that are intended to provide more targeted, specialised … Continued
